ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $86.00 price target on the stock.
IBD 50 Stock Flashes 'Golden Cross' But Massive Risk Looms [Yahoo! Finance]
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report? [Yahoo! Finance]
Peptide Antibiotics Industry Report 2025 | Antibiotic Resistance Crisis Fuels Demand as Market Surges Toward USD 8.4 Billion [Yahoo! Finance]
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET